A registrational program evaluating INCA033989 for the treatment of patients with myelofibrosis
Latest Information Update: 02 Mar 2026
At a glance
- Drugs INCA 033989 (Primary)
- Indications Myelofibrosis
- Focus Registrational; Therapeutic Use
Most Recent Events
- 10 Feb 2026 According to Incyte Corporation media release, company plan to initiate the trial in second half of 2026.
- 16 Dec 2025 New trial record
- 07 Dec 2025 According to Incyte Corporation media release, company paln to initiate the trial in 2026.